Working to make the promise of precision medicine a reality
P. Ron Ellis
Chief Executive Officer/President
P. Ron Ellis is one of our founders and has served as our president and chief executive officer since 1996 and as a member of our Board of Directors since 1995. Prior to joining Endocyte, Mr. Ellis was with Hill-Rom Company, the $1.2 billion healthcare division of Hillenbrand Industries. While at Hill-Rom, he held a variety of senior management positions, including vice president of strategy/corporate development and vice president of the specialty care division. Mr. Ellis holds a BS in computer science and an MBA from Brigham Young University, and a certification in regulatory affairs from Purdue University.
Mike A. Sherman
Chief Financial Officer
Mike A. Sherman has served as our chief financial officer since 2006. Previously, Mr. Sherman served in various executive roles, most recently as vice president of finance and strategic planning of Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation, a medical device company. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth. He also serves on the Indianapolis Children’s Museum Board of Trustees.
Philip S. Low, PhD
Chief Science Officer
Dr. Philip S. Low is one of our founders and has served as our chief science officer since 1998 and as a member of our Board of Directors since 1995. Dr. Low has served on the faculty at Purdue University since August 1976, where he is currently the Ralph C. Corley Distinguished Professor of Chemistry. He holds a BS in chemistry from Brigham Young University and a PhD in biochemistry from the University of California, San Diego.
Chief Commercial Officer
David Meek has served as our chief commercial officer since August 2012. He was previously head of oncology at Novartis Oncology for northern, central, and eastern Europe. In this role, he oversaw the launches of numerous key new oncology products and indications, including TASIGNA® and AFINITOR®. Prior to this, he served as president and chief executive officer for Novartis Canada where he led the successful launches of key specialty products. He also served as the global business franchise head for the Novartis respiratory and dermatology franchise in Basel, Switzerland. Prior to joining Novartis, Mr. Meek was at Johnson & Johnson for 15 years, where he held a variety of executive sales and marketing roles across multiple therapeutic areas, including oncology. Before beginning his pharmaceutical career, he was a commissioned officer in the US Army, achieving the rank of captain. Mr. Meek holds a BA from the University of Cincinnati.
Michael A. Brinkley
Vice President of Quality
Michael Brinkley has served as vice president of quality since June 2013. From January 2012 to June 2013, Mr. Brinkley served as director of quality for Endocyte. Prior to joining Endocyte, Mr. Brinkley spent 30 years in the pharmaceutical industry in analytical chemistry, microbiology, and quality assurance. Mr. Brinkley holds a BS in microbiology from North Carolina State University and an MBA from the University of North Carolina, Chapel Hill.
Vice President of Business Development
Matthew Call joined Endocyte in 2003 as director of business development and has served as vice president of business development since 2012. He is responsible for all strategic partnering and licensing transactions. Mr. Call has led numerous successful partnering processes, including Endocyte’s transformational billion-dollar partnership with Merck for vintafolide. Prior to joining Endocyte, Mr. Call spent several years working in business development in information technology, where he structured and managed strategic relationships with firms such as Hewlett-Packard, General Electric, First Data Corporation, and Disney. He received a BA from Brigham Young University and an MBA from Purdue University.
Scot L. Harper, PhD
Vice President of Clinical Operations
Scot L. Harper, Ph.D., joined the company as vice president of clinical operations in May 2013. Previously, he was vice president of clinical operations at Novartis and senior director of clinical operations at Eli Lilly and Company. He also served as oncology medical director for Lilly’s US affiliate. Dr. Harper received his doctorate in medical physiology from Indiana University School of Medicine and an MBA from the University of South Alabama, where he served on the faculty of the College of Medicine. He received his undergraduate degree from DePauw University.
Christopher P. Leamon, PhD
Vice President of Research & Development
Dr. Christopher P. Leamon has served as our vice president of research and development since 2000. From 1999 to 2000, Dr. Leamon served as our director of biology and biochemistry. Prior to joining us, Dr. Leamon was employed in the pharmaceutical industry where he conducted discovery research in the field of peptide, oligonucleotide, liposome, and DNA drug delivery for Glaxo Wellcome, a healthcare company, and Isis Pharmaceuticals, a biomedical pharmaceutical company. He holds a BS in chemistry from Baldwin Wallace College and a PhD in biochemistry from Purdue University.
Chandra D. Lovejoy
Vice President of Regulatory Affairs
Chandra D. Lovejoy has served as our vice president of regulatory affairs since 2010. From 2007 to 2010, she served as our director of regulatory affairs. Ms. Lovejoy served in various positions at Genentech, a biotechnology company and an indirectly wholly owned subsidiary of Roche Holdings, a healthcare company, including manager of regulatory affairs and senior associate of regulatory affairs. She holds a BS in organizational behavior from the University of San Francisco and an MS in regulatory affairs from San Diego State University.
Binh Nguyen MD, PhD
Vice President of Medical Affairs
Dr. Binh Nguyen has served as our vice president of medical affairs since 2011. He was previously chief medical officer at Tigris Pharmaceuticals. Prior to this, he worked at Eli Lilly and Company for 10 years, most recently as executive director, global oncology platform team, for which he was responsible for the global development of Gemzar®, ALIMTA®, and Enzastaurin. Dr. Nguyen received his PhD in organic chemistry from Georgetown University and his MD from the University of Maryland. He completed fellowships at the National Cancer Institute and worked at the FDA’s Division of Oncology as a medical reviewer.
Allen R. Ritter, PhD
Vice President of Manufacturing/CMC
Dr. Allen R. Ritter has served as our vice president of manufacturing and chemistry manufacturing control (CMC) since December 2005. From 2004 to 2005, Dr. Ritter served as our director of development, CMC and manufacturing. Dr. Ritter holds a BS in chemistry from St. Olaf College, an MS in organic chemistry from the University of Pittsburgh, and a PhD in synthetic organic chemistry from the University of Notre Dame.
Iontcho Vlahov, PhD
Vice President of Discovery Chemistry
Dr. Iontcho Vlahov joined Endocyte in 1999 and serves as the vice president of discovery chemistry. He received his PhD in synthetic organic and structural chemistry from Ruhr University, Bochum, Germany. Before joining Endocyte, he was the head of discovery chemistry at Ivax Corp in Miami, Florida. Prior to that, he held various positions, including visiting scientist at Hercules, Inc.; senior research scientist at the University of Konstanz, Germany; research scientist at the Institute of Organic Chemistry, Bulgarian Academy of Sciences; and research associate at the University of Iowa. Dr. Vlahov is an Alexander von Humboldt Fellow and has published more than 55 scientific articles and 15 patents. His main interest is the synthesis of complex biologically active molecules and the design of novel organic reactions. Currently, Dr. Vlahov’s research is committed to the discovery and development of novel conjugates ensuring intracellular release of folate-targeted chemotherapeutic agents.